• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Akili + Roblox Form First of Its Kind Digital Treatment Partnership

by Jasmine Pennic 05/31/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Akili + Roblox Form First of Its Kind Digital Treatment Partnership

What You Should Know:

– Akili’s EndeavorRx, the first and only FDA-cleared video game ADHD treatment for kids, is uniting with Roblox’s global virtual universes forming a first-of-its-kind partnership. 

– Initially, the partnership will establish an exclusive Roblox reward exchange for patients that complete their medically prescribed EndeavorRx treatment. The rewards will enable patients to redeem items via the exchange program as soon as this summer. 

Delivering A Reimagined Patient Experience

For many, adhering to treatments can be tough. A study showed that 54% of children taking oral stimulants for ADHD are not adhering to their treatment. This partnership establishes new ways for medicine to fit seamlessly into patients’ lives, combining an entertaining cognitive treatment with the immersive and 3D shared experiences of the Roblox platform to make taking your medicine fun and rewarding.

EndeavorRx Indication and Overview

EndeavorRx® is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx® demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx® should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx® is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication.

EndeavorRx® associated adverse events in clinical trials included frustration (6.1%), headache (1.3%), dizziness (0.6%), emotional reaction (0.4%), nausea (0.4%), and aggression (0.2%). No serious adverse events were associated with its use. EndeavorRx® is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child’s health care provider. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Clinical Trials, FDA, medication, Patient Experience, video

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

The Real Risk in Healthcare AI Isn’t the Model. It’s the Data. 

Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |